- Home
- PHUN vs PLUR Comparison
PHUN vs PLUR Comparison
Compare PHUN & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHUN | PLUR |
|---|---|---|
| Founded | 2009 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1M | 33.9M |
| IPO Year | 2016 | 2001 |
Fundamental Metrics
Financial Performance| Metric | PHUN | PLUR |
|---|---|---|
| Price | $1.72 | $3.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $7.25 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 91.8K | 5.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,883,000.00 | $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | $95.95 | $293.97 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 15.57 | ★ 309.82 |
| 52 Week Low | $1.56 | $2.82 |
| 52 Week High | $3.88 | $7.13 |
Technical Indicators
Market Signals| Indicator | PHUN | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 47.04 | 45.60 |
| Support Level | $1.60 | $3.13 |
| Resistance Level | $2.04 | $3.42 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 52.05 | 20.34 |
Price Performance
Historical ComparisonAbout PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About PLUR Pluri Inc.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.